Prolor Biotech Inc. (AMEX: PBTH; TASE: PBTH) is beginning the Phase II clinical trial of its human growth hormone, hGH-CTP.
Prolor develops proteins for therapeutic purposes, with a focus on developing improved versions of current biological drugs. The company's technology can extend the effectiveness of drugs in the body. hGH-CTP is the most is the farthest along in the company's pipeline.
hGH-CTP is a long-term growth hormone for children and adults who lack the hormone. Prolor's objective is an injection of hGH-CTP once every week or two, instead of the current treatments, which have be injected every day.
The Phase I clinical trial of hGH-CTP demonstrated the potential of reducing injections from once a day to twice a month. The Phase II trial will be held at fourteen medical centers in six countries to test hGH-CTP's tolerance and effectiveness at different dosages.
Prolor CEO Dr. Abraham Havron said that he hopes that the Phase II trial will enable the company to plan the proper dosage of the hormone. "Growth hormone treatments require many years of daily injections," he said. "We hope that we can offer patients a better solution."
Ness Ziona-based Prolor closed yesterday at $6.74 on the American Stock Exchange, giving a market cap of $311 million. The share price fell 1.1% by mid-afternoon on the TASE to NIS 26.21.
Published by Globes [online], Israel business news - www.globes-online.com - on July 21, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010